FDA approves Zilbrysq autoinjector for daily self-injection in generalized myasthenia gravis

Overview

Updated Oct 27

Adults with generalized myasthenia gravis (gMG, a disease that weakens voluntary muscles) can now take their daily Zilbrysq dose with a spring-loaded autoinjector instead of a prefilled syringe. The FDA approved the device on October 16. In a study of 100 people, 90% completed a first injection with no training.

The device matters because gMG can weaken the hands, and a syringe needs grip and careful technique. The autoinjector fires a preset dose when pressed against the skin. Zilbrysq still carries an FDA boxed warning for serious meningococcal infections, so patients need meningococcal vaccines first and the drug is limited to a restricted safety program. UCB expects the autoinjector to be sold in the first quarter of 2027.

Why it matters

gMG patients now need less hand strength and zero training to self-inject daily, letting more treat themselves at home without a caregiver.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

99.8%

Complete dose delivery rate

In a Phase 3b study of 31 gMG patients, 99.8% of 449 autoinjector administrations delivered the full dose.

90%

First-attempt success without training

90 of 100 participants in a human factors study completed their first injection with no prior instruction.

Self-administration options for ZILBRYSQ

The drug is now available as a prefilled syringe or an autoinjector in the United States. The autoinjector is expected in commercial sale in Q1 2027.

9.7%

Injection site pain rate

The most common treatment-emergent adverse event in the Phase 3b autoinjector study, reported by 3 of 31 patients.

0.98–1.00

Dose-delivery ratio vs syringe

Geometric least-squares mean ratios for AUC and Cmax comparing the autoinjector with the prefilled syringe in a 14-person Phase 1 crossover study, all within the 90% confidence bounds.

EUR 203.00

UCB share price, Oct 18

UCB shares traded at EUR 203.00 in weekend trading at Lang & Schwarz on October 18, two days after the approval.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Kimberly Moran, PhD

Senior Vice President and Head, U.S. Rare Diseases at UCB

Leads U.S. rare disease commercialization for UCB

Donatello Crocetta

Global Head of Medical Affairs and Chief Medical Officer at UCB

Leads global medical affairs for UCB

Organizations Involved

US Children's Bureau

Federal Agency

Developer and marketer of ZILBRYSQ

Brussels-based biopharmaceutical company with two approved generalized myasthenia gravis therapies.

U.S. Food and Drug Administration

Federal regulator

Approved the ZILBRYSQ autoinjector

The U.S. agency responsible for approving and regulating drugs and medical devices.

Timeline

October 2023 October 2026

3 events Latest: October 16th, 2026 · 4 weeks ago

October 2026
FDA approves Zilbrysq autoinjector
Latest Approval

FDA approved the ZILBRYSQ autoinjector, the first once-daily subcutaneous autoinjector for gMG in the US, adding a second self-administration option.
October 16th, 2026
March 2026
EU medicines committee recommends pre-filled pen
Regulatory

The EMA's Committee for Medicinal Products for Human Use recommended approval of the zilucoplan pre-filled pen presentation, reported in AANEM 2026 coverage.
March 2026
October 2023
FDA approves Zilbrysq prefilled syringe
Approval

FDA cleared ZILBRYSQ (zilucoplan), a once-daily subcutaneous injection for anti-AChR positive adults with gMG.
October 17th, 2023

Scenarios

Autoinjector Lifts Zilbrysq Uptake in First Full Sales Quarters

Possible Resolves by Aug 31, 2027

Discussed by: Deutsche Bank analysts cited in MarketScreener coverage of the approval

If the autoinjector makes ZILBRYSQ easier to take, more gMG patients and prescribers may choose it. UCB's quarterly earnings through 2027 would show whether the device converts into prescriptions. The autoinjector launches in Q1 2027, making the first full measurement period the second quarter.

European Approval Extends Autoinjector Beyond the US

Possible Resolves by End of 2027

Discussed by: Industry analysts tracking UCB's international regulatory pathway

UCB is a Belgian company with European operations, and an EMA submission for the autoinjector would follow the US clearance. European gMG patients would gain the same convenience if the device is approved there. UCB has not publicly announced an EMA submission timeline.

Competing gMG Therapies Respond With Their Own Devices

Uncertain Resolves by End of 2027

Discussed by: Neuromuscular disease market observers

Rival gMG treatments delivered by infusion or manual syringe may face pressure to offer easier self-administration. A comparable device approval for another gMG drug would signal that delivery convenience has become a competitive battleground. No competitor has announced such a plan as of the approval date.

European Commission Adopts Pre-Filled Pen for Zilbrysq

Likely Resolves by Q2 2027

Discussed by: NeurologyLive coverage of AANEM 2026 data

The EMA's medicines committee already recommended the zilucoplan pre-filled pen in March 2026, before the US autoinjector approval. A final European Commission decision would give European gMG patients the same self-injection convenience that US patients gained in October 2026.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

October 2023

ZILBRYSQ prefilled syringe approval (2023)

The FDA approved ZILBRYSQ (zilucoplan) as a once-daily subcutaneous injection for adults with anti-AChR antibody positive gMG. The approval was based on a 12-week randomized, placebo-controlled trial of 174 patients showing a 2.1-point greater improvement on the MG-ADL daily function scale versus placebo.

Then

ZILBRYSQ became the first complement inhibitor designed for patient self-administration rather than clinic-based IV infusion.

Now

It established that C5 inhibition could work as an at-home daily therapy, setting the stage for device improvements.

Why this matters now

The autoinjector is the second iteration of this delivery model, reducing the dexterity and training required for the same daily dose.

2000s to present

Biologic self-injection devices in chronic disease (2000s-present)

Over two decades, biologic drugs for chronic conditions such as rheumatoid arthritis, psoriasis, and multiple sclerosis migrated from clinic-administered IVs or manual syringes to pen and autoinjector devices designed for home use. Devices like the EpiPen established the spring-loaded autoinjector model now common across drug classes.

Then

Patients gained independence from clinic visits for routine dosing, and device design reduced the skill required for injection.

Now

Autoinjectors became a standard expectation for self-administered biologics across therapeutic areas.

Why this matters now

ZILBRYSQ's autoinjector applies this established device model to a rare neuromuscular disease where muscle weakness makes syringe handling especially difficult.

Sources

(9)